Now, AstraZeneca's Covid vaccine linked to VITT blood clotting disorder: Report
The vaccine was linked to Vaccine-Induced Immune Thrombocytopenia and Thrombosis
The vaccine was linked to Vaccine-Induced Immune Thrombocytopenia and Thrombosis
The vaccine was linked to Vaccine-Induced Immune Thrombocytopenia and Thrombosis
The vaccine was linked to Vaccine-Induced Immune Thrombocytopenia and Thrombosis
AstraZeneca's coronavirus vaccine, which was sold in India as Covishield, is linked to a rare blood clotting disorder called Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT), researchers have found.
Pharmaceutical company AstraZeneca earlier this month had announced the worldwide withdrawal of its Covid-19 vaccines. Although "surplus of available updated vaccines" that target new variants of the virus was cited as the reason for the withdrawal, the decision came days after the company acknowledged in court papers that the vaccine carried serious side effects, known as thrombosis with thrombocytopenia, or TTS, in some people. This also follows the AstraZeneca's decision to withdraw its European Union marketing authorisation. On May 6, Monday, the European Medicines Agency issued a notice that the vaccine is no longer authorised for use.
It was scientists of South Australia's Flinders University that revealed in a study VITT emerged in 2021 during the Covid-19 pandemic, particularly after the use of the Oxford-AstraZeneca vaccine. The jab was based on adenovirus vectors, India Today said in a report.